AVAvalo Therapeutics, Inc. AVTX · NASDAQ
$12.26 -0.81% (-$0.10)
- Market cap
- $657.5M
- Enterprise value
- $572.4M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 11,144.1x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -19.5%
- Bruto marža
- -16,861.0%
- Neto marža
- -170,056.0%
- Dividend yield
- -
- Payout ratio
- -
- Neto dolg/EBITDA
- -
- Beta
- 0.79
- Free float
- 89.6%
O podjetju
Avalo Therapeutics is an American biopharmaceutical company focused on developing medicines for the treatment of cancer and autoimmune diseases. The company specializes in utilizing innovative therapeutic approaches, including immunotherapy and targeted therapy, to identify and treat various types of cancer. Their research and development efforts are aimed at discovering new drug compounds and therapeutic methods that could improve the lives of patients and bring new hope to the field of cancer treatment. Avalo Therapeutics shares could be an interesting choice for investors looking for opportunities in the biotechnology sector and drug development for cancer.
Sector
Healthcare
Industry
Biotechnology
CEO
Garry A. Neil
Employees
33
Headquarters
Wayne
Vrednotenje
Je današnja cena primerna?
Rast in ocene
Ali podjetje raste in kaj sledi?
Donosnost in kakovost
Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?
Finančno zdravje
Ali zmore svoj dolg?
Kapital in dividende
Kaj podjetje počne z zasluženim denarjem?
Analitiki
Kaj menijo strokovnjaki in ali se to spreminja?
Lastniki in insajderji
Kdo ima delnice in kaj počne vodstvo?
Segmenti
Kateri del podjetja raste?
Primerjava s konkurenco
Kako se primerja s podobnimi podjetji?
Cena in tveganje
Kako se delnica obnaša?
Izkazi
Vse številke